- EFV: not recommended in pregnant women or women with no reliable and consistent contraception; not active on HIV-2 and HIV-1 group O
- Contra-indicated if HLA B*5701 positive. Even if HLA B*5701 negative, counselling on HSR risk still mandatory
- ABC + NVP contra-indicated, unless HLA B*5701 negative
- Abacavir should be used with caution in patients with a high cardiovascular risk and/or patients with a viral load higher than 100,000 copies/ml.
- NVP: Use with extreme caution in women with CD4 >250 and men with CD4 >400/μL; not active on HIV-2 and HIV-1 group O
- Castle study (LPV/r vs ATV/r) has shown better tolerability of ATV/r and Artemis study (LPV/r vs DRV/r) better efficacy and greater tolerability of DRV/r.
- ACTG 5142, randomised study showed lower virological efficacy of LPV/r vs EFV. However no PI mutations were seen in the LPV/r failures.
- Only if unavailable or intolerant to other recommended NRTIs
- Raltegravir is indicated in combination with other anti-retroviral medicinal products for the treatment HIV-1 infection in adult patients. It has been studied only in combination with TDF/FTC in naïve patients with limited follow-up (48 weeks).
|
